Pulmatrix, Inc. (NASDAQ:PULM) Short Interest Up 106.2% in April

Pulmatrix, Inc. (NASDAQ:PULM) was the recipient of a significant increase in short interest in April. As of April 30th, there was short interest totaling 40,413 shares, an increase of 106.2% from the April 15th total of 19,602 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average trading volume of 43,030 shares, the days-to-cover ratio is currently 0.9 days.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pulmatrix in a research note on Friday, March 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Institutional Trading of Pulmatrix

A hedge fund recently bought a new stake in Pulmatrix stock. DRW Securities LLC bought a new stake in Pulmatrix, Inc. (NASDAQ:PULM) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor bought 20,505 shares of the biotechnology company’s stock, valued at approximately $46,000. Institutional investors and hedge funds own 11.84% of the company’s stock.

Pulmatrix Stock Performance

Shares of Pulmatrix stock traded down $0.02 on Friday, hitting $1.25. The stock had a trading volume of 17,492 shares, compared to its average volume of 31,072. The stock has a 50 day moving average of $1.56 and a 200 day moving average of $2.73. Pulmatrix has a twelve month low of $1.16 and a twelve month high of $9.37. The firm has a market capitalization of $4.56 million, a P/E ratio of -0.89 and a beta of 1.94.

Pulmatrix (NASDAQ:PULM) last released its quarterly earnings data on Friday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

About Pulmatrix

Pulmatrix, Inc is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA).